Compare Fubotv Inc (FUBO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Summit Therapeutics Inc — how do they compare? Fubotv Inc trades at $9.6 (market cap $1.06B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 11.4× Fubotv Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | SMMT | |
|---|---|---|
Market Cap | $1.06B | $12.06B |
Sector | Technology | Health |
52-Week High | $54.72 | $26.98 |
52-Week Low | $8.09 | $12.55 |
Enterprise Value | $1.23B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.45, up 0.96% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion, beating expectations, and raised its full-year adjusted EBITDA outlook to $90–$100 million. Valuation ratios appear attractive with a P/E of 2.53 and P/S of 0.19, while recent leadership changes include the appointment of former Disney executive Alisa Bowen as CEO.
The outlook is positive as FUBO shows improving financials and strategic partnerships, but risks include persistent net losses and high debt. Analyst consensus is a Buy with a $15.33 price target, suggesting significant upside potential if profitability goals are met.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
